Biospec

Description

BiospecDMX264 is a pharmaceutical compound characterized by its specific molecular structure and properties. The chemical formula and molecular weight are integral to its classification and application in medical settings. This compound is formulated in a dosage form suitable for its intended use, ensuring optimal delivery and efficacy. The appearance of BiospecDMX264 is consistent with its formulation standards, contributing to its identification and handling in professional environments.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with minor throat and bronchial irritation, which may occur due to colds. Additionally, it aids in loosening phlegm (mucus) and thinning bronchial secretions, thereby making coughs more productive.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 12 years and older are advised to take 2 teaspoonfuls (10 mL) every 4 hours, not exceeding 8 teaspoonfuls in a 24-hour period. For children aged 6 years to under 12 years, the recommended dosage is 1 teaspoonful every 4 hours. Children aged 2 years to under 6 years should receive 1/2 teaspoonful every 4 hours. For children under 2 years of age, it is essential to consult a doctor before administration.

Healthcare professionals should ensure that patients are aware of the maximum dosage limit and the importance of adhering to the recommended intervals to avoid potential overdose.

Contraindications

Use is contraindicated in patients who experience a cough lasting more than 7 days, a recurrent cough, or a cough accompanied by fever, rash, or persistent headache. These symptoms may indicate a serious underlying condition that requires medical evaluation.

Warnings and Precautions

It is imperative to adhere strictly to the recommended dosage when using this product. Exceeding the prescribed amount may lead to adverse effects. Additionally, this product should not be used concurrently with prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Furthermore, it is contraindicated to use this product for at least two weeks following the discontinuation of an MAOI. Healthcare professionals should advise patients to consult their doctor or pharmacist if they are uncertain about the presence of an MAOI in their current medications.

Healthcare providers should exercise caution and recommend that patients seek medical advice prior to use if they present with a cough that is productive of excessive phlegm (mucus), or if the cough is chronic, as seen in conditions such as smoking, asthma, chronic bronchitis, or emphysema. Patients should be directed to consult a physician if their cough is accompanied by excessive mucus unless otherwise instructed by a healthcare professional.

In the event of an overdose, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Patients should be advised to discontinue use and consult their doctor if their cough persists for more than seven days, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache. These symptoms may indicate a more serious underlying condition that requires further evaluation.

Side Effects

Patients should be aware of the potential adverse reactions associated with this product. It is crucial not to exceed the recommended dosage, as doing so may lead to serious complications. Additionally, the use of this product is contraindicated in patients currently taking a prescription monoamine oxidase inhibitor (MAOI) or within two weeks of discontinuing such medication. MAOIs are commonly prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Patients uncertain about their current medications should consult their doctor or pharmacist prior to use.

Before using this product, patients should seek medical advice if they experience a cough that is accompanied by excessive phlegm (mucus), or if the cough persists or is associated with smoking, asthma, chronic bronchitis, or emphysema. These conditions may require specific medical evaluation and intervention.

Drug Interactions

The concomitant use of this product with monoamine oxidase inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, certain psychiatric disorders, or Parkinson’s disease. Patients should not initiate treatment with this product if they are currently taking an MAOI or have taken one within the past two weeks.

It is essential for patients to consult with their healthcare provider or pharmacist to confirm whether they are using any prescription medications that contain an MAOI prior to starting this product. This precaution is critical to avoid potential serious interactions that may arise from the combination of these agents.

Packaging & NDC

Below are the non-prescription pack sizes of Biospec (dextromethorphan, guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older are recommended to take 2 teaspoonfuls (10 mL) every 4 hours. For children aged 6 years to under 12 years, the dosage is 1 teaspoonful every 4 hours. In children aged 2 years to under 6 years, the appropriate dosage is 1/2 teaspoonful every 4 hours. For infants and children under 2 years of age, it is advised to consult a doctor before administration.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution and consider individual patient factors when prescribing to patients with reduced kidney function, as the absence of specific guidance necessitates careful clinical judgment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

Exceeding the recommended dosage of the medication can lead to serious health consequences. It is imperative that healthcare professionals adhere strictly to the prescribed dosage guidelines to mitigate the risk of overdosage.

In the event of suspected overdosage, it is crucial to monitor the patient closely for any potential symptoms that may arise. Symptoms of overdosage can vary depending on the specific medication involved and may include a range of physiological and psychological effects.

Management of overdosage should be initiated promptly. Healthcare professionals are advised to assess the patient's condition and provide supportive care as necessary. This may include symptomatic treatment and monitoring of vital signs. In cases where the overdosage is significant, further medical intervention may be required, including the consideration of activated charcoal or other decontamination methods, depending on the time elapsed since ingestion and the specific circumstances of the case.

It is essential for healthcare providers to remain vigilant and to educate patients about the importance of adhering to prescribed dosages to prevent the occurrence of overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions reported voluntarily or through surveillance programs. These include allergic reactions such as rash, pruritus, and urticaria. Neurological effects such as dizziness, drowsiness, confusion, and hallucinations have also been noted. Gastrointestinal disturbances, including nausea and vomiting, were reported alongside cardiovascular effects such as increased heart rate (tachycardia) and elevated blood pressure.

Additionally, respiratory depression and hepatotoxicity, characterized by elevated liver enzymes, have been observed. The occurrence of serotonin syndrome has been particularly noted when the product is used in conjunction with other serotonergic agents. Skin reactions, including Stevens-Johnson syndrome, and other central nervous system effects have also been documented during postmarketing surveillance of the product.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion.

In the event of an overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center for assistance.

Patients should also be informed to discontinue use and consult a doctor if their cough persists for more than 7 days, returns, or is accompanied by symptoms such as fever, rash, or a persistent headache. These symptoms may indicate a serious underlying condition that requires medical evaluation.

Storage and Handling

The product is supplied in packaging that includes specific NDC numbers, which should be referenced for identification. It is essential to store the product at room temperature, maintaining a range of 15-30°C (59-86°F).

Healthcare professionals are advised to inspect the product prior to use. The product should not be utilized if the seal under the cap or the cello-band over the cap is torn, broken, or missing, as this may compromise the integrity of the product. Proper handling and storage conditions are crucial to ensure the product's efficacy and safety.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Biospec, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)